Actively Recruiting

Phase Not Applicable
Age: 50Years - 85Years
All Genders
NCT06539806

Clinical Study Evaluating the Effect of Losartan

Led by Tanta University · Updated on 2024-08-06

90

Participants Needed

1

Research Sites

108 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The pancreas is two organs packaged into one. The islets of Langerhans serve critical endocrine functions, and the exocrine portion is a major source of enzymes that are essential for digestion. Pancreatic cancer (PC) is more commonly referred to as pancreatic infiltrating ductal adenocarcinoma in addition to being the second leading cause of cancer death in the United States, after lung cancer in 2020. Whereas pancreatic cancer is the seventh cause of death from cancer in Asia in 2020. Although it is substantially less common than the other malignancies, pancreatic carcinoma is near the top of the list of killers because it is a highly aggressive carry.

CONDITIONS

Official Title

Clinical Study Evaluating the Effect of Losartan

Who Can Participate

Age: 50Years - 85Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Male and female pancreatic cancer patients aged 250 years old.
  • Hypertensive patients with blood pressure 2140/90 mm Hg.
  • Patients with histologically confirmed metastatic pancreatic adenocarcinoma or locally advanced pancreatic cancer.
  • Patients who have signed an informed consent form.
Not Eligible

You will not qualify if you...

  • Patients with serious systemic disorders affecting the heart, kidneys, liver, or lungs.
  • Pregnant or breastfeeding women and women who can become pregnant.
  • Patients who have received systemic fluoropyrimidine therapy in the past 10 years.
  • Patients with severe allergic reactions to fluoropyrimidine therapy, 5-fluorouracil, irinotecan, oxaliplatin, losartan, or any monoclonal antibody.
  • Patients with active or suspected autoimmune diseases like psoriasis.
  • Patients who tested positive for hepatitis B or C, HIV, or AIDS.
  • Patients who received live or live attenuated vaccines, including intranasal influenza vaccines, within 30 days before starting the study therapy.

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Tanta University Hospital

Tanta, Egypt

Actively Recruiting

Loading map...

Research Team

M

Mona Abd El-Rafea Mohamed, M.D

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here